The OX40-TRAF6 axis promotes CTLA-4 degradation to augment antitumor CD8+ T-cell immunity
J Yu, J Cui, X Zhang, H Xu, Z Chen, Y Li… - Cellular & Molecular …, 2023 - nature.com
Immune checkpoint blockade (ICB), including anti-cytotoxic T-lymphocyte associated protein
4 (CTLA-4), benefits only a limited number of patients with cancer. Understanding the in …
4 (CTLA-4), benefits only a limited number of patients with cancer. Understanding the in …
The E3 ubiquitin ligase TRAF6 controls CTLA-4 turnover and promotes T-cell-mediated antitumor immunity
XL Jie, H Guo, GB Zhou - Cellular & Molecular Immunology, 2024 - nature.com
Yu et al.[1] reported that the tumor necrosis factor (TNF) receptor OX40 (CD134)-TNF
receptor-associated factor 6 (TRAF6) axis mediates Lys63-linked ubiquitination and …
receptor-associated factor 6 (TRAF6) axis mediates Lys63-linked ubiquitination and …
Double‐negative T cells regulate the progression of liver fibrosis through Th9 cells differentiation
C Han, H Pei, Y Sheng, J Wang, X Zhou, W Li… - Liver …, 2023 - Wiley Online Library
Our previous study found that double negative T cells (DNTs) could promote the NLRP3
activation through high expression of TNF‐α, thereby leading to hepatic fibrosis progression …
activation through high expression of TNF‐α, thereby leading to hepatic fibrosis progression …
[HTML][HTML] Redox Signaling Modulates Activity of Immune Checkpoint Inhibitors in Cancer Patients
Although immunotherapy is already a staple of cancer care, many patients may not benefit
from these cutting-edge treatments. A crucial field of research now focuses on figuring out …
from these cutting-edge treatments. A crucial field of research now focuses on figuring out …